Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1224 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanidatamab for treating advanced or metastatic HER2-positive biliary tract cancer in adults Zanidatamab (ZW-25) Biliary tract cancer Gastrointestinal Cancer 2023 View  |  Download
Zanubrutinib for previously treated mantle cell lymphoma Zanubrutinib (BGB-3111; Brukinsa) Mantle cell lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for treating marginal zone lymphoma Zanubrutinib (BGB-3111; Brukinsa) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for Waldenstrom's Macroglobulinemia Zanubrutinib (BGB-3111; Brukinsa) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2018 View  |  Download
Zanubrutinib plus obinutuzumab for treating relapsed or refractory follicular lymphoma Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Zanubrutinib (BGB-3111; Brukinsa) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Zavegepant for treating acute migraine Zavegepant (BHV-3500) Migraine Neurology 2024 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications